Sickle Cell Disease Clinical Trial
Official title:
Analysis of T-Cell Immune Reconstitution Following Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease (ImmuneReconstSCD)
In this study, patient blood samples from NMA transplants will be provided by Pittsburgh, and samples from myeloablative transplants will be provided by Atlanta (comparative controls). Samples would be obtained pre- and post-BMT from the recipient at a total of 7 timepoints, and from the donor at one timepoint.
Sickle cell disease (SCD) is a serious inherited disorder of red blood cells that shortens
life and causes life-long problems. One of the most common genetic diseases in America, SCD
affects 1 of every 375 African-American live births, and can be identified by routine
newborn screening. SCD manifests with vaso-occlusive events, the most common of which is the
"sickle pain crisis," which causes severe and unrelenting pain, typically in the back,
chest, or long bones. Other types of vaso-occlusive events involve the spleen, brain
(stoke), retina, bones, kidney and lungs. Patients are at increased risk for death due to
bacterial infections, damage to vital organs, or aplastic crisis (failure to produce any red
cells), and often suffer chronic organ damage.
Patients with frequent and severe complications in early childhood are typically felt to be
at highest risk for continued debilitating problems and early death. These severely affected
children have been the subject of efforts to cure SCD through bone marrow transplantation
(BMT) from a healthy donor. BMT is curative for SCD because it provides a source of normal
hemoglobin production. BMT is performed by giving the patient high doses of chemotherapy,
then infusing bone marrow from a healthy donor into a large vein in the recipient, followed
by an intensive period of supportive care and immune suppression. Over 200 patients with SCD
have been transplanted world-wide, primarily from sibling donors who are HLA (tissue or
transplantation type) matched. Of those transplanted in a North American cooperative study,
about 95% of these patients survived the transplant, and about 85% are free of sickle cell
disease. The Atlanta program was the largest contributor to this study. Through 2004,
Atlanta has transplanted 18 children with SCD from matched siblings; all are free of sickle
cell disease and none have died.
Because conventional (myeloablative) BMT carries significant risks of morbidity and
mortality ant thus limits its use, researchers have recently been investigating less risky
methods of BMT for SCD, called reduced intensity or non-myeloablative (NMA) transplant. Dr.
Catherine Wu of the Dana Farber Cancer Institute and Dr. Laksmannan Krishnamurti of the
Children's Hospital of Pittsburgh are both performing NMA transplant for adults (Wu) and
children (Krishnamurti) with severe SCD. In Atlanta (Haight), patients continue to be
offered transplant using the conventional myeloablative approach.
Important questions remain about the functional and long-term status of transplanted SCD
patients in a variety of areas; this study will focus upon immune function. Because little
is know about the functional immune status of patients after non-myeloablative transplants,
and certainly not those who undergo transplantation for the diagnosis of sickle cell anemia,
patient blood samples will be analyzed for extent of immune reconstitution following
transplant through immunophenotyping of various immune cell subsets, molecular analysis of
reconstitution of T cell neogenesis (TREC analysis) and T cell receptor complexity (TCR
Vbeta spectratyping).
;
Observational Model: Cohort
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Completed |
NCT02620488 -
A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease
|
N/A | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 |